Samsung Biologics records sales of KRW 125.4 billion and profits of KRW 23.7 billion in 2Q 2018
Samsung Biologics Co., Ltd. (CEO: Tae Han Kim) today announced its business performance for the second quarter in 2018. The company posted quarterly sales of KRW 125.4 billion and operating profits of KRW 23.7 billion.
Sales at Plant 2 increased but total quarterly sales fell by KRW 5.6 billion (4.3%) compared to last quarter due to production preparation for new products at Plant 1, driven by the movement of products from Plant 1 to Plant 2.
However, operating profit of Samsung Biologics increased sharply by KRW 13.7 billion (137%), from the previous quarter owing to an increase in the capacity utilization rate at Plant 2 that is highly efficient.
Net loss records KRW 9.6 billion but it increased by KRW 47.6 billion (83.3% QoQ) due to the improvement of sales performance of the company’s subsidiary Samsung Bioepis.
※ Samsung Biologics Financial Result 2Q 2018 (Billion KRW)
'18. 2Q | '18. 1Q | QoQ | '17. 2Q | YoY | |
Sales | 125.4 | 131 | -5.6(-4.3%) | 63.2 | +62.2(98.4%) |
Operating Profit | 23.7 | 10 | 13.7(137.2%) | -8.5 | +32.2(378.8%) |
Net Profit | -9.6 | -57.2 | 47.6(83.3%) | -22.1 | +12.5(56.6%) |
- The End -
Samsung Biologics records sales of KRW 125.4 billion and profits of KRW 23.7 billion in 2Q 2018
Samsung Biologics Co., Ltd. (CEO: Tae Han Kim) today announced its business performance for the second quarter in 2018. The company posted quarterly sales of KRW 125.4 billion and operating profits of KRW 23.7 billion.
Sales at Plant 2 increased but total quarterly sales fell by KRW 5.6 billion (4.3%) compared to last quarter due to production preparation for new products at Plant 1, driven by the movement of products from Plant 1 to Plant 2.
However, operating profit of Samsung Biologics increased sharply by KRW 13.7 billion (137%), from the previous quarter owing to an increase in the capacity utilization rate at Plant 2 that is highly efficient.
Net loss records KRW 9.6 billion but it increased by KRW 47.6 billion (83.3% QoQ) due to the improvement of sales performance of the company’s subsidiary Samsung Bioepis.
※ Samsung Biologics Financial Result 2Q 2018 (Billion KRW)
'18. 2Q | '18. 1Q | QoQ | '17. 2Q | YoY | |
Sales | 125.4 | 131 | -5.6(-4.3%) | 63.2 | +62.2(98.4%) |
Operating Profit | 23.7 | 10 | 13.7(137.2%) | -8.5 | +32.2(378.8%) |
Net Profit | -9.6 | -57.2 | 47.6(83.3%) | -22.1 | +12.5(56.6%) |
- The End -
Share article
Related Content